This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year.
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how IPSEN (IPSEY) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
by Zacks Equity Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
by Zacks Equity Research
Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.
ASRT vs. IPSEY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. IPSEY: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Daimler, E.ON, BASF, Telecom Italia and Ipsen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Daimler, E.ON, BASF, Telecom Italia and Ipsen
ECB Paves Way for More Stimulus! Grab 5 European Stocks Now
by Tirthankar Chakraborty
ECB leaves room for more stimulus measures and an uptick in Eurozone economic growth make European stocks more alluring
Bellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher
by Zacks Equity Research
Bellicum Pharmaceuticals (BLCM) was a big mover last session, as the company saw its shares rise nearly 14% on the day.
Why IPSEN (IPSEY) Could Be an Impressive Growth Stock
by Zacks Equity Research
IPSEN (IPSEY) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations
Commercial Vehicle Group, MTS Systems, Ipsen, AXA and Arkema highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Commercial Vehicle Group, MTS Systems, Ipsen, AXA and Arkema highlighted as Zacks Bull and Bear of the Day
The U.S.A. and China Start Talking: Global Week Ahead
by John Blank
China's President Xi meets President Trump in Florida later this week, and traders will watch it closely.